Mixed tubulopapillary hidradenoma and syringocystadenoma papilliferum
occurring as a verrucous tumor.
Hsu PJ, Liu CH, Huang CJ.
Department of Dermatology, China Medical College Hospital,
Taichung, Taiwan. |
`J Cutan Pathol 2003 Mar;30(3):206-10 Abstract quote
Tubulopapillary hidradenoma (TPH)1 is a term proposed to describe morphological
dermal ductal tumors with both eccrine and apocrine differentiation.
The term TPH encompasses a spectrum of lesions that includes tubular
apocrine adenoma (TAA) and papillary eccrine adenoma (PEA):2 PEA and
TAA can be indistinguishable both clinically and histologically.
We described a case of TPH with both prominent eccrine and apocrine
differentiation combined with syringocystadenoma papilliferum (SCAP)
over the distal extremity. This rarely encountered dermatopathological
phenomenon is the sixth reported case from the literature in which PEA
or TAA and SCAP were present in the same lesion.3-7 Furthermore, the
tumor had a warty surface, which is histologically consistent with a
typical viral verruca.
Although PCR and DNA probe hybridization for human papilloma virus
(HPV) types 2, 6/11, 16 and 18 failed to reveal positive results, the
location and clinicopathologic correlation convinced us that superimposed
HPV could not be excluded. |
Ductal carcinoma arising from a syringocystadenoma papilliferum in a nevus sebaceus of Jadassohn.
Hugel H, Requena L.
Dermatohispathologische Gemeinschaftspraxis, Friedrichshafen, Germany.
|
Am J Dermatopathol. 2003 Dec;25(6):490-3 Abstract quote. |
|
We present an example of ductal carcinoma connected to a syringocystadenoma papilliferum situated in a nevus sebaceus of Jadassohn on the scalp of a 22-year-old woman. The ductal carcinoma involved the entire thickness of the dermis and extended to the subcutaneous fat. Because syringocystadenoma papilliferum is considered a hamartoma with apocrine differentiation, the ductal carcinoma here described was interpreted as an apocrine ductal carcinoma.
Syringocystadenocarcinoma papilliferum is an exceedingly rare neoplasm, most examples of which seem to have arisen in its benign counterpart, syringocystadenoma papilliferum. From a histopathologic point of view, syringocystadenocarcinoma papilliferum usually shows a papillary configuration similar to that of syringocystadenoma papilliferum. In contrast, the case here described a ductal carcinoma superficially connected to a syringocystadenoma papilliferum, but mostly composed of small ductal structures embedded in a desmoplastic stroma and involving the full thickness of the dermis.
We review the literature about the malignant neoplasms arising in the nevus sebaceus of Jadassohn. |
Syringocystadenocarcinoma papilliferum: Case report
and immunohistochemical comparison with its benign counterpart
Akemi Ishida-Yamamoto, MD, PhD
Katsuhiko Sato, MD
Takashi Wada, MD
Hidetoshi Takahashi, MD, PhD
Hajime Iizuka, MD, PhD
Asahikawa, Japan |
J Am Acad Dermatol 2001;45:755-9 Abstract quote
Syringocystadenocarcinoma papilliferum (SCACP) is the malignant counterpart
of syringocystadenoma papilliferum (SCAP), although only a few cases
have been reported in the literature and its clinical and histologic
characteristics are not well known.
We report a case of SCACP that started as an enlarging nodule over
10 years in the perianal area of a 61-year-old man. Macroscopically,
the lesion was a black exophytic tumor, 6 cm in diameter, with a granular
surface. Histologically, it was an in situ adenocarcinoma, showing cytologic
atypia and pagetoid spread in the surrounding epithelia, although the
clinicopathologic features were distinct from extramammary Paget's disease.
The tumor lacked the typical double-layered pattern of SCAP but had
some similar histopathologic features to SCAP. Decapitation secretion
was apparent and there was positive immunoreactivity to epithelial membrane
antigen and human milk fat globules subclass 2.
SCACP is a rare cutaneous tumor but nevertheless represents a specific
dermatopathologic entity. |